Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis
NCT02221258Phase 1Completed
- Sponsor
- Kangstem Biotech
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FURESTEM-RA in rheumatoid arthritis (RA), sponsored by Kangstem Biotech. Primary endpoint: Safety of FURESTEM-RA Inj. treatment at 4 weeks. Started Oct 2014; status: completed.
02
Drugs
FURESTEM-RA
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02221258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221258.